Ameriprise Financial Inc Kronos Bio, Inc. Transaction History

Ameriprise Financial Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$1.34 - $2.62 $49,802 - $97,374	37,166 Added 38.78%	133,015 $194,000
Q4 2022 Feb 14, 2023	SELL	$1.44 - $3.44 $12,083 - $28,865	-8,391 Reduced 8.05%	95,849 $155,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $17,855 - $29,581	5,330 Added 5.39%	104,240 $349,000
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $31,536 - $76,012	10,108 Added 11.38%	98,910 $360,000
Q1 2022 May 16, 2022	BUY	$6.26 - $14.42 $297,650 - $685,642	47,548 Added 115.26%	88,802 $642,000
Q4 2021 Feb 14, 2022	SELL	$11.35 - $21.18 $21,565 - $40,242	-1,900 Reduced 4.4%	41,254 $561,000
Q3 2021 Nov 15, 2021	BUY	$18.17 - $24.7 $67,901 - $92,303	3,737 Added 9.48%	43,154 $905,000
Q2 2021 Aug 16, 2021	BUY	$20.08 - $29.02 $68,392 - $98,842	3,406 Added 9.46%	39,417 $944,000
Q1 2021 May 17, 2021	SELL	$27.0 - $32.48 $210,033 - $252,661	-7,779 Reduced 17.76%	36,011 $1.05 Million
Q4 2020 Feb 12, 2021	BUY	$26.68 - $38.23 $1.17 Million - $1.67 Million	43,790 New	43,790 $1.31 Million

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $55.1M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Ameriprise Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Ameriprise Financial Inc with notifications on news.